EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions

Supriya Peshin iD, Adit Dharia, Nagaishwarya Moka, William Paul Skelton iD

Cancers · 26.09.2025 · 17 (19) · 3139

DOI: 10.3390/cancers17193139 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.09.2025. Verfasst von Supriya Peshin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: William Paul Skelton IV.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) is a biologically diverse malignancy with a rising global incidence and a high propensity for metastasis, particularly in its clear cell subtype. While traditional treatments have centered on surgery and targeted therapies, immunotherapy has emerged as a transformative approach in the management of advanced RCC. This review explores the evolution of immunotherapy in RCC, from early cytokine-based treatments to the advent of immune checkpoint inhibitors (ICIs) and their integration with tyrosine kinase inhibitors (TKIs). We detail the immunologic mechanisms underpinning these therapies, the rationale from preclinical models, and the pivotal clinical trials that redefined standard of care. Challenges such as immune resistance, tumor heterogeneity, and immune escape mechanisms are critically analyzed, highlighting tumor-intrinsic and microenvironmental factors. Lastly, we examine ongoing innovations including novel immune checkpoints, cytokine modulators, CAR-T therapies, and neoantigen-based vaccines, offering a forward-looking perspective on enhancing immunotherapeutic efficacy and personalization in RCC management.

Schlagwörter

Stichwörter der Autor:innen

CLTA-4PD-1advanced RCCbelzutifanimmune checkpoint inhibitorsimmunotherapyrenal cell carcinomatyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA.
  • Department of Internal Medicine, HCA Florida Oak Hill Hospital, Brooksville, FL 34613, USA.
  • Department of Hematology and Oncology, Lincoln Memorial University, Harrogate, TN 38105, USA.
  • Department of Medicine, Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA 22908, USA.

ORCID-Profile: Supriya Peshin, William Paul Skelton

Förderung

  • William Paul Skelton IV

Zitieren

APA

Peshin, S., Dharia, A., Moka, N., & Skelton, W. P. (2025). A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions. Cancers, 17(19), 3139. https://doi.org/10.3390/cancers17193139

Vancouver

Peshin S, Dharia A, Moka N, Skelton WP. A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions. Cancers. 2025;17(19):3139. doi:10.3390/cancers17193139

BibTeX
@article{Peshin2025,
  author = {Peshin, Supriya and Dharia, Adit and Moka, Nagaishwarya and Skelton, William Paul},
  title = {A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {19},
  pages = {3139},
  doi = {10.3390/cancers17193139}
}
Kostenlos starten →